CClinicalTrials.gg
Status unknownNCT03088683Updated Mar 23, 2017

Comparison of Liver Trauma in Two Retractors Used in Sleeve Gastrectomy

An interventional study of Nathanson Retractor and Reveel Retractor in Obesity, sponsored by Umraniye Education and Research Hospital. Status unknown at 1 site in Turkey. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-23.

Sponsored by Umraniye Education and Research Hospital · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Mar 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

In Laparoscopic Sleeve Gastrectomy, retraction of the left lobe of the liver is important for an effective visualisation. There are many retractors available for this retraction. A study is designed to compare two different liver retractors for liver trauma; Nathanson liver retractor that is used more commonly and Reveel liver retractor that has more recent history of use.

Read the detailed description

A randomised controlled prospective study is designed with 80 patients over 3-month period (January 2017 to March 2017). Laparoscopic sleeve gastrectomy is planned for all patients. Two groups are designed depending on retractor. Liver retraction will be provided with Nathanson retractor in first group (Nathanson group, 40 patients), and with Reveel retractor in second group (Reveel group, 40 patients). Preoperative serum levels of transaminases, total bilirubin and C-reactive protein will be measured in all patients. The same biochemical markers will be measured on days 1 and 2 postoperatively. The patients with body mass index (BMI) ≥35kg/m2 are enrolled to study. The parameters of demographic characteristics (age, gender, BMI, weight, and body fat percentage), and clinical outcomes (postoperative complications, mortality, readmissions) are planned to record.

Operative Technique

All patients will be operated by same surgeons. and anesthetist. Peroperatively intravenous paracetamol 10 mg, tramadol 50 mg and fentanyl 150 mcg will be used for analgesia. Laparoscopic sleeve gastrectomy will be performed with 5 trocars, in reverse trendelenburg position by creating pneumoperitoneum with 14 mmHg carbon dioxide insufflation. Trocar replacements are one 10-mm trocar in the midline above umbilicus for the endoscope, one 12-mm trocar to right midclavicular line linage to the 10-mm trocar. One 5-mm trocar to the left midclavicular line linage to the 10-mm trocar, one 5-mm trocar to the front axillary line below the left costal margin. Both liver retractors will be placed from 2 cm below the xiphoid process for liver retractor. In nathanson group; after placing the blade of Nathanson retractor below the left lobe of the liver, it will be fixed to the operating table by the other instruments of retractor. In reveel group; the retractor will be placed below the left lobe of the liver and then it will be fixed to the skin with a towel clamp. 38 F orogastric tube will be used. No use of nasogastric tubes and urinary catheters routinely is planned. Drain replacement is planned for all patients.

Preoperative and postoperative values of the markers will be analysed and compared between two groups.

02

Conditions studied

  • Obesity

Keywords

  • sleeve gastrectomy
  • liver retractor
  • nathanson
  • reveel
  • liver trauma
03

In context

Lead sponsor

Umraniye Education and Research Hospital is the lead sponsor of 60 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • patients with BMI>35

Exclusion criteria

Exclusion Criteria:

  • patients with known liver disease
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Nathanson Retractor

    Nathanson retractor will be used

    Device: Nathanson Retractor

  • Active comparator
    Reveel Retractor

    Reveel retractor will be used

    Device: Reveel Retractor

Interventions

  • DeviceNathanson Retractor

    Liver will be retracted with Nathanson retractor

  • DeviceReveel Retractor

    Liver will be retracted with Reveel retractor

06

What researchers measure

Primary outcomes

  1. Changes in physiological parameters of liver due to trauma of retractors

    Traumatic effects of liver retractors in sleeve gastrectomy. Number of participants with abnormal laboratory values.

    Time frame: within the first 2 days of the surgery

07

Study locations

1 of 1 sites recruiting
  • Nazif Bagriacik Kadioy Hospital
    Istanbul, Kadikoy, Turkey
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03088683
Lead sponsor
Umraniye Education and Research Hospital
Responsible party
Abdullah Sisik (General Surgery Specialist, Umraniye Education and Research Hospital) — Principal investigator
First posted
Mar 23, 2017
Start date
Jan 2017
Primary completion
Apr 1, 2017 (estimated)
Completion
Apr 20, 2017 (estimated)
Last update
Mar 23, 2017

Study contacts

Abdullah Sisik
Contact
abdullahsisik@gmail.com
00905062623325
Abdullah Sisik
principal investigator · Umraniye Education and Research Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion